Evidence map›Paper›PMID 33803723›Full record

ArticleJournal of clinical medicine2021

Blue Laser (450 nm) in the Treatment of Port Wine Stains and Telangiectasia.

Jacek Szymańczyk, Witold Trzeciakowski, Yurij Ivonyak, Piotr Tuchowski, Janusz Szymańczyk

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Rhinophyma Treatment with Blue Laser.Iranian journal of otorhinolaryngology · 2025
    Article
  3. Blue Laser (450 nm) Treatment of Solar Lentigines.Journal of clinical medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jacek SzymańczykDepartment of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland.
Witold TrzeciakowskiInstitute of High Pressure Physics, Polish Academy of Sciences, Sokołowska 29/37, 01-142 Warsaw, Poland.ORCID 0000-0002-4871-1069
Yurij IvonyakInstitute of High Pressure Physics, Polish Academy of Sciences, Sokołowska 29/37, 01-142 Warsaw, Poland.
Piotr TuchowskiAccuro Ltd., Zawodzie 16, 02-981 Warsaw, Poland.
Janusz SzymańczykDepartment of Dermatology and Venerology, Medical University of Łódź, 90-643 Łódź, Poland.
Institute of High Pressure Physics · PLMedical University of Warsaw · PL

Funding

Narodowe Centrum Badań i Rozwoju PBS3/A7/18/2015
6 · The paper itself

Abstract

This study aimed to test a blue light source for the treatment of port wine stains (PWS) and telangiectasia and to compare this with the application of green and yellow lasers based on data in the literature. A total of 22 patients with PWS were treated with radiation from a novel, high-power 450 nm blue laser that was created for this project. The group contained 15 patients with red PWS and 7 with pink PWS. The best results were achieved for red PWS, using 15-20 ms light pulses and 47 W power. For patients with pink malformations, the results were unsatisfactory. The group with telangiectasia consisted of six patients with facial lesions and three with leg lesions. The recovery was completed for all patients with facial telangiectasia, while the blue laser therapy was ineffective for patients with leg telangiectasia. This study shows that, in some cases, the use of a blue laser may be an alternative to the use of green and yellow lasers.

Indexed as

blue laserfacial and leg telangiectasialaser therapyport wine stainsvascular malformations

Identifiers

PMID33803723
PMCPMC8003022
OpenAlexW3136727656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.